Belantamab mafodotin (Belamaf) is the first FDA approved, B-cell maturation antigen (BCMA) targeting ADC in triple-class exposed, relapsed and/or refractory MM beyond four prior lines of therapy. Belamaf is now being combined with other drug classes in earlier lines of therapy. There are...
介绍一种IL15-Trispecific Killer Engagers (TriKE) ,能够使自然杀伤细胞对CD33+靶点具有特异性,同时也诱导持久性、体内扩张和增强功能。 目的 输注NK细胞诱导白血病缓解的有效治疗受到抗原特异性和缺乏体内扩增的限制。为了解决第一个问题,作者...
This technology, known as GlycoConnect, has been adapted by various drug developers (e.g. ADC Therapeutics, Mersana Therapeutics and others) and is now applied in two (2) clinical programs as well as multiple late-stage preclinical programs.Here we demonstrate how GlycoConnect technology can be...